✦ LIBER ✦

470 HBeAg negative patients with chronic hepatitis B are less likely to have A biochemical breakthrough during lamivudine treatment

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hepatitis B surface antigen seroconversi

✍ R. Idilman; K. Cinar; G. Seven; Y. Bozkus; A. Elhan; M. Bozdayi; C. Yurdaydin; K 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

Optimal duration of additional therapy a

✍ Masaru Enomoto; Akihiro Tamori; Madoka Toyama Kohmoto; Takehiro Hayashi; Hiroyas 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB